Last reviewed · How we verify
NCT05894746
Gfree - For Improved Blood Sugar and Reduced Inflammation.
NA trial testing gluten-free in Diabetes in 60 participants. Currently enrolling.
1 December 2025
Quick facts
| Lead sponsor | Göteborg University |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | crossover |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 60 |
| Start date | 4 May 2023 |
| Primary completion | 1 December 2025 |
| Estimated completion | 31 December 2030 |
| Sites | 2 locations across Sweden |
Drugs / interventions tested
- gluten-free
- probiotic
- gluten
Conditions studied
- Diabetes — all drugs for Diabetes →
- Celiac Disease — all drugs for Celiac Disease →
- Autoimmunity — all drugs for Autoimmunity →
- Metabolic Disease — all drugs for Metabolic Disease →
Sponsor
Göteborg University
Who can join
6 and older, any sex, with Diabetes or Celiac Disease. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to reduce inflammation and improve glycemic control in healthy volunteers, parents, as well as children, adolescents and adults with or without diabetes. The main questions it aims to answer are: • does a reduction wheat gluten improve glycemic control and/or inflammatory biomarkers • does a reduction in certain amino acids (which is most common in wheat gluten) improve glycemic control and/or inflammatory biomarkers • can we identify individuals with an inflammatory response, which leads to poor glycemic control. Participants will eat gluten-free products as well as similar products containing gluten. They will also eat gluten together with probiotics to see if an effect of gluten can be reduced. Researchers will compare everyone with themselves (cross-over design) and if possible individuals with and without diabetes.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05894746
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Diabetes
Currently open trials in the same condition.
- NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
- NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
- NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
- NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
- NCT07417865 — ECHO Diabetes FQHC · recruiting
Other Göteborg University trials
Trials by the same sponsor.
- NCT07260604 — HIFEM for Incontinence After Menopause High-Intensity Focused Electromagnetic (HIFEM) · NA · not yet recruiting
- NCT07401420 — Life Sustaining Treatments in Critically Ill Children · not yet recruiting
- NCT07213245 — Metabolic Effects of Short-term Ultra-processed Food Intake (MEST-UPF) · NA · recruiting
- NCT07178405 — Effects of Meal Characteristics on Appetite · NA · completed
- NCT07172841 — Non-invasive Diagnostics of Shunt Obstruction in Adult Hydrocephalus · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05894746 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Göteborg University
- Last refreshed: 15 October 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05894746.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing